Hone Bio (previously Cytoseek) has developed a novel cell membrane augmentation technology, enabling the addition of new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability.
A spin-out from the University of Bristol, Hone Bio’s technology is based on the research of Dr Adam Perriman, who pioneered a new methodology for the rational design of synthetic artificial membrane-binding proteins.
